<DOC>
	<DOC>NCT00828971</DOC>
	<brief_summary>The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure infection.</brief_summary>
	<brief_title>A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs</brief_title>
	<detailed_description />
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Written informed consent Men or women of age &gt;/= 18 years with a diagnosis of bacterial skin and skin structure infection that requires Hospitalization Initial parenteral therapy for at least 48 hours Complicated by at least one of the following criteria: Involvement of deep soft tissues (e.g. fascial, muscle layers) Requirement for a significant surgical intervention including surgical drainage, drainage procedure guided by imaging and/or debridement Association with a significant underlying disease that may complicate response to treatment. Presence of SIRS (Systemic Inflammatory Response Syndrome) defined as two or more of the following signs or symptoms: temperature &gt; 38.3°C or &lt; 36°C white blood cell count &gt; 12.000/mmc or &lt; 4.000 or &gt; 10% bands pulse rate &gt; 90 beats/min respiratory rate &gt; 20178 systolic blood pressure &lt;/= 90 mmgHg decreased capillary refill/mottling &gt; 2 seconds lactate &gt; 2 mmol/L altered mental status hyperglycemia &gt; 120 mg/dl or 7.7 mmol/L in the absence of diabetes protein C (CPR) &gt; 20 mg/L (VR 05)3. Duration of infection &lt; 21 days Diagnosis of one of the following skin and skin structure infections: major abscess(es) associates with extensive cellulitis erysipelas and cellulitis infected pressure ulcers(s) wound infections including: post surgical (surgical incision), post traumatic, human bite/clenched fist and animal bite wound and wound associated with injection drug abuse Infected ischemic ulcers with at least one of the following conditions: Diabetes mellitus Peripheral vascular disease Conditions predisposing to pressure scores such as paraplegia or peripheral neuropathy Presence of at least 3 of the following local signs and symptoms purulent drainage or discharge erythema extended &gt;1 cm from the wound edge fluctuance pain or tenderness to palpation swelling or induration fever defined as body temperature &gt; 37.5°C (axillary), &gt; 38°C (orally), &gt; 38.5°C (tympanically), or &gt; 39°C (rectally). OR Elevated total peripheral white blood cell (WBC) count&gt; 12,000/mm3 OR &gt; 15% immature neutrophils (blends) regardless of total peripheral WBC count Creactive protein (CRP) &gt;20 mg/L Women, who are pregnant or lactating, or in whom pregnancy can not be excluded (Note: a urine pregnancy test has to be performed for all women of childbearing potential before randomization to the study drug). The following skin and skin structure infections: Necrotizing fasciitis including Fournier's gangrene, ecthyma gangrenosum, streptococcal necrotizing fasciitis and clostridial necrotizing fasciitis. Burn wound infections. Secondary infections of a chronic skin disease (eg, atopic dermatitis). Infection of prosthetic materials. Subjects with removal of a prosthetic device involved in an infection should not be included. Infections where a surgical procedure alone is definitive therapy. Subjects with uncomplicated skin and skin structure infections including</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Complicated skin and skin structure infections</keyword>
	<keyword>cSSSI</keyword>
</DOC>